<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006127</url>
  </required_header>
  <id_info>
    <org_study_id>199/15281</org_study_id>
    <secondary_id>DFCI-9910170</secondary_id>
    <secondary_id>ALZA-99-004-ii</secondary_id>
    <nct_id>NCT00006127</nct_id>
  </id_info>
  <brief_title>Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the toxicity of amifostine in patients with bone marrow failure related to&#xD;
      Fanconi's anemia.&#xD;
&#xD;
      II. Determine the efficacy of this treatment regimen in this patient population.&#xD;
&#xD;
      III. Evaluate the effect of this treatment regimen on bone marrow progenitor cell&#xD;
      proliferation and peripheral blood mononuclear cell apoptosis in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      This is a dose escalation study.&#xD;
&#xD;
      Patients receive amifostine IV over 3-5 minutes three times a week for three weeks.&#xD;
&#xD;
      Cohorts of 3 patients receive one of three dose levels of amifostine. The maximum tolerated&#xD;
      dose is defined as the dose preceding that at which 2 of 6 patients experience dose limiting&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed weekly for 3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2000</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>21</enrollment>
  <condition>Fanconi's Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Diagnosis of Fanconi's anemia by conventional diepoxybutane or mitomycin sensitivity&#xD;
        assays, or molecular testing&#xD;
&#xD;
        Bone marrow failure verified on at least 3 occasions in the preceding 3 months by any one&#xD;
        of the following: hemoglobin less than 8 g/dL; absolute neutrophil count less than&#xD;
        1,000/mm3; platelet count less than 30,000/mm3; symptomatic bone marrow failure (e.g.,&#xD;
        exercise limitation from anemia or spontaneous bleeding from thrombocytopenia)&#xD;
&#xD;
        Evidence consistent with myelodysplastic syndrome allowed if less than 5% blasts on bone&#xD;
        marrow aspiration; clonality on bone marrow cytogenetic analysis OR morphological changes&#xD;
        on bone marrow aspirate&#xD;
&#xD;
        Refusal of or unsuccessful with prior conventional therapies&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        Biologic therapy: No prior bone marrow transplantation; no concurrent hematopoietic growth&#xD;
        factors&#xD;
&#xD;
        Endocrine therapy: No concurrent androgens&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hepatic: Bilirubin no greater than 2 times normal AST no greater than 3 times normal ALT no&#xD;
        greater than 6 times normal&#xD;
&#xD;
        Renal: Creatinine no greater than 2 times normal&#xD;
&#xD;
        Other: No prior malignancy; no active bacterial, viral, or fungal infection requiring&#xD;
        therapy other than prophylaxis; not pregnant; negative pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Nicholas Haining</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>August 3, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Fanconi's anemia</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

